Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study

Title: Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study
Authors: Cazzaniga, Marina Elena; Pronzato, Paolo; Amoroso, Domenico; Bernardo, Antonio; Biganzoli, Laura; Bisagni, Giancarlo; Blasi, Livio; Bria, Emilio; Cognetti, Francesco; Crinò, Lucio; De Laurentiis, Michelino; Del Mastro, Lucia; De Placido, Sabino; Beano, Alessandra; Ferraù, Francesco; Foladore, Silva; Forcignanò, Rosachiara; Gamucci, Teresa; Garrone, Ornella; Gennari, Alessandra; Giordano, Monica; Giotta, Francesco; Giovanardi, Filippo; Latini, Luciano; Livi, Lorenzo; Marchetti, Paolo; Mattioli, Rodolfo; Michelotti, Andrea; Montemurro, Filippo; Putzu, Carlo; Riccardi, Ferdinando; Ricciardi, Giuseppina; Romagnoli, Emanuela; Sarobba, Giuseppina; Spazzapan, Simon; Tagliaferri, Pierosandro; Tinari, Nicola; Tonini, Giuseppe; Turletti, Anna; Verusio, Claudio; Zambelli, Alberto; Mustacchi, Giorgio
Contributors: Cazzaniga, Marina Elena; Pronzato, Paolo; Amoroso, Domenico; Bernardo, Antonio; Biganzoli, Laura; Bisagni, Giancarlo; Blasi, Livio; Bria, Emilio; Cognetti, Francesco; Crinò, Lucio; De Laurentiis, Michelino; Del Mastro, Lucia; De Placido, Sabino; Beano, Alessandra; Ferraù, Francesco; Foladore, Silva; Forcignanò, Rosachiara; Gamucci, Teresa; Garrone, Ornella; Gennari, Alessandra; Giordano, Monica; Giotta, Francesco; Giovanardi, Filippo; Latini, Luciano; Livi, Lorenzo; Marchetti, Paolo; Mattioli, Rodolfo; Michelotti, Andrea; Montemurro, Filippo; Putzu, Carlo; Riccardi, Ferdinando; Ricciardi, Giuseppina; Romagnoli, Emanuela; Sarobba, Giuseppina; Spazzapan, Simon; Tagliaferri, Pierosandro; Tinari, Nicola; Tonini, Giuseppe; Turletti, Anna; Verusio, Claudio; Zambelli, Alberto; Mustacchi, Giorgio
Publisher Information: MDPI; ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
Publication Year: 2023
Collection: Università degli Studi di Genova: CINECA IRIS
Subject Terms: HER2 negative; metastatic breast cancer; overall survival; progression free survival; time to treatment change
Description: Simple Summary Breast cancer is one of the most common oncological diseases among women in Western Countries and Italy as well. GIM 13-AMBRA is a patient journey study regarding how the prognosis of metastatic breast cancer patients has changed in the last decades as a result of the introduction of new drugs in clinical practice. This study also provides information regarding the different natural histories of breast cancer according to the presence or absence of hormone receptors and HER2 receptors.Abstract GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes-based regimens, or taxanes + targeted agents, mainly Bevacizumab, were the preferred first choice in both Luminal (30.2%) and TNBC (33.3%) patients. The median PFS1 was 12.5 months (95% CI 16.79-19.64), without any significant difference according to subtypes, while the median Time to first Treatment Change (TTC1) was significantly lower in TNBC patients (7.7 months-95% CI 5.7-9.2) in comparison to Luminal A (13.2 months, 95% CI 11.7-15.1) and Luminal B patients (11.8 months, 95% CI 10.3-12.8). PFS2 was significantly shorter in TNBC patients (5.5 months, 95% CI 4.3-6.5 vs. Luminal A-9.4, 95% CI 8.1-10.7, and Luminal B-7.7 95% CI 6.8-8.2, F-Ratio 4.30, p = 0.014). TTC2 was significantly lower in patients with TNBC than in those with the other two subtypes. The median OS1 was 35.2 months (95% CI 30.8-37.4) for Luminal A patients, which was significantly higher than that for both Luminal B (28.9 months, 95% CI 26.2-31.2) and TNBC (18.5 months, 95% CI 16-20.1, F-ratio 7.44, p = 0.0006). The GIM 13-AMBRA study is one of the largest collections ever published in Italy and provides useful results in terms of time outcomes for first, second, and further lines of treatment in HER2- MBC patients.
Document Type: article in journal/newspaper
File Description: STAMPA
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/38201545; info:eu-repo/semantics/altIdentifier/wos/WOS:001139188300001; volume:16; firstpage:1; lastpage:11; numberofpages:11; journal:CANCERS; https://hdl.handle.net/11567/1161288
DOI: 10.3390/cancers16010117
Availability: https://hdl.handle.net/11567/1161288; https://doi.org/10.3390/cancers16010117
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.CD4EEFB5
Database: BASE